semaglutide studies 2024 Long-term weight loss effects of in obesity without diabetes in the SELECT trial AHA 2024: semaglutide continues to

Communicate with the brain to reduce appetite and cravings

That matters because it affects how cases are categorized, how evidence is presented, and potentially how damages are calculated

After a year of taking semaglutide, marketed as Wegovy by Novo Nordisk, patients risk of suffering from conditions like a heart attack or a stroke over the next 10 years dropped to 6.3% from 7.6% when measured by a commonly used calculator, researchers at the Mayo Clinic found

10 GLP-1, a peptide hormone, is generated by enteroendocrine cells at low baseline levels and by neurons in the caudal medulla

For example, researchers behind one small randomized controlled trial found that participants with obesity who ate half a fresh grapefruit before each meal for 12 weeks lost an average of 1.6 kilograms (kg), or about 3.5 pounds (lb), compared with a control group who lost 0.3 kg, which is less than 1 lb

Here's a closer look